Correlation Between Biotechnology Ultrasector and Guidepath Income

Can any of the company-specific risk be diversified away by investing in both Biotechnology Ultrasector and Guidepath Income at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotechnology Ultrasector and Guidepath Income into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Biotechnology Ultrasector Profund and Guidepath Income, you can compare the effects of market volatilities on Biotechnology Ultrasector and Guidepath Income and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotechnology Ultrasector with a short position of Guidepath Income. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotechnology Ultrasector and Guidepath Income.

Diversification Opportunities for Biotechnology Ultrasector and Guidepath Income

0.75

Correlation Coefficient

Biotechnology Ultrasector  Guidepath Income

Poor diversification

The 3 months correlation between Biotechnology and Guidepath is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Biotechnology Ultrasector Prof and Guidepath Income in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Guidepath Income and Biotechnology Ultrasector is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biotechnology Ultrasector Profund are associated (or correlated) with Guidepath Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Guidepath Income has no effect on the direction of Biotechnology Ultrasector i.e., Biotechnology Ultrasector and Guidepath Income go up and down completely randomly.

Pair Corralation between Biotechnology Ultrasector and Guidepath Income

Assuming the 90 days horizon Biotechnology Ultrasector Profund is expected to generate 8.56 times more return on investment than Guidepath Income. However, Biotechnology Ultrasector is 8.56 times more volatile than Guidepath Income. It trades about 0.13 of its potential returns per unit of risk. Guidepath Income is currently generating about 0.19 per unit of risk. If you would invest  3,791  in Biotechnology Ultrasector Profund on May 20, 2025 and sell it today you would earn a total of  603.00  from holding Biotechnology Ultrasector Profund or generate 15.91% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Biotechnology Ultrasector Prof  vs.  Guidepath Income

Biotechnology Ultrasector

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Biotechnology Ultrasector Profund are ranked lower than 10 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak forward indicators, Biotechnology Ultrasector showed solid returns over the last few months and may actually be approaching a breakup point.

Guidepath Income

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Guidepath Income are ranked lower than 14 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly strong basic indicators, Guidepath Income is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Biotechnology Ultrasector and Guidepath Income

The main advantage of trading using opposite Biotechnology Ultrasector and Guidepath Income positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotechnology Ultrasector position performs unexpectedly, Guidepath Income can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Guidepath Income will offset losses from the drop in Guidepath Income's long position.

The idea behind Biotechnology Ultrasector Profund and Guidepath Income pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.